米格列醇与阿卡波糖治疗2型糖尿病的临床疗效及不良反应比较

目的对米格列醇与阿卡波糖治疗2型糖尿病的疗效及不良反应进行评价比较。方法选择我院2012年11月至2013年12月住院治疗的2型糖尿病患者80例,随机分为米格列醇组和阿卡波糖组,每组40例,比较治疗前及1、2、3个疗程过程中的血糖、血脂等指标的变化,并记录不良反应发生率。结果两种药物均具有较好的降血糖作用,尤其对餐后高血糖症状缓解较为明显,第3个疗程结束后,两组患者的HbA1c均降低,但是米格列醇组较阿卡波糖组尤为明显,差异有统计学意义(P<0.05);两组患者的TG较治疗前显著降低,HDL显著升高,差异有统计学意义(P<0.05),但TC的变化不显著。整个治疗过程中,两组患者都有不同程度的胃肠道不良反应,但米格列醇组较轻微,随着用药时间延长,这些症状均会缓解,未见严重不良反应现象。结论阿卡波糖和米格列醇均为一种安全有效的口服降糖药物,米格列醇略优。

Compared the Clinical Efficacy and Adverse Reaction of Miglitol and Acarbose in Treating Type 2 Diabetes

Objective To compared the clinical efficacy and adverse reaction of miglitol and acarbose in treating type 2 diabetes. Methods Choose 80 cases from Nov. 2012 to Dec. 2012 in our hospital as study object, were randomly divided into miglitol group of 40 cases and acarbose group of 40 cases, two groups were observed before treatment and treated after one, two and three treatment period in patients with blood-lipid and glucose levels and change, recorded the incidence rate of adverse reaction between the two groups. Results Both miglitol and acarbose could decreased the glucose levels in patients, especial the postprandial 2 hour blood glucose, after the third treatment period, the HbA1c in two groups were decreased, but the amount in the miglitol group was significant, there is a statistically significant difference（P〈0.05）. In both groups, the TG levels were decreased, but the HDL levels were increased, there is a statistically significant difference（P〈0.05）, the change in TC levels were not significant. In the whole treatment period, different degrees of gastrointestinal adverse reactions were observed in both groups, but the miglitol group was slighter, with the time gone, the symptoms will alleviate, no serious adverse reactions was observed. Conclusion Both miglitol and acarbose are safe and efficient, but miglitol is more excellent.